__'''DCM, PPI,SEM'''__<
>
You can download a copy of Charlotte and Emma's talks here: [[attachment:DCM.ppt]], [[attachment:connectivity.pptx]] <
>
__'''Web Resources'''__<
>
Below is a list of web resources used in the talk <
>
'''DCM'''<
><
>
[[http://imaging.mrc-cbu.cam.ac.uk/imaging/ConIG|ConIG]]<
>
CBU's Connectivity Interest Group. In particular, see Rik’s and James’ talks (“Introduction to DCM”; “Advanced DCM”)
[[http://www.fil.ion.ucl.ac.uk/spm/doc/manual.pdf|SPM Manual]]<
>
SPM Manual,pg 299-312.
__'''References'''__<
>
'''PPI and SEM'''<
><
>
J.B. Rowe, L.E. Hughes, R.A. Barker,& A.M. Owen (2010). Dynamic causal modelling of effective connectivity from fMRI: Are results reproducible and sensitive to Parkinson's disease and its treatment? Neuroimage, 52(3): 1015–1026.<
>
[[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3021391/|DOI:10.1016/j.neuroimage.2009.12.080]]<
><
>
Rowe et al. (2002) Attention to action in Parkinson’s disease: impaired effective connectivity among frontal cortical regions. Brain, 125:276-289 <
>
[[http://eprints.ucl.ac.uk/143615/|Abstract]]
'''DCM'''<
><
>
The original DCM paper <
>
Friston KJ, Harrison L, Penny W, (2003). Dynamic causal modelling.Neuroimage,19(4):1273-302.<
>
[[http://www.ncbi.nlm.nih.gov/pubmed/12948688/|PMID: 12948688]]<
><
>
Stephan KE, Penny WD, Moran RJ, et al.,(2010).Ten simple rules for dynamic causal modeling. Neuroimage, 15;49(4):3099-109.<
>
[[http://www.ncbi.nlm.nih.gov/pubmed?term=Neuroimage%2C%2049%3A3099-3109/|PMID: 19914382]]<
>
'''Example Applications of DCM'''<
>
Ewbank, M., Lawson, R., Henson, R.N., Rowe, J., Passamonti, L. & Calder, C. (2011). Changes in 'top-down' connectivity underlie repetition suppression in the ventral visual pathway. Journal of Neuroscience, 31, 5635-5642. <
>
[[http://www.ncbi.nlm.nih.gov/pubmed?term=Journal%20of%20Neuroscience%2C%2031%2C%205635-5642/|PMID: 21490204]] <
>
Rowe J. B., Hughes L. E., Barker R. A., Owen A. M. (2010). Dynamic causal modelling of effective connectivity from fMRI: are results reproducible and sensitive to Parkinson's disease and its treatment? Neuroimage 52, 1015–1026. doi: 10.1016/j.neuroimage.2009.12.080.<
>
[[http://www.ncbi.nlm.nih.gov/pubmed?term=Neuroimage%2C%2052%3A1015-1026/|PMID: 20056151]]